Literature DB >> 24362689

The adaptive immune response to respiratory syncytial virus.

Steven M Varga1, Thomas J Braciale.   

Abstract

Respiratory syncytial virus (RSV) causes severe respiratory disease in children, the elderly and immunocompromised individuals. The combined actions of CD4 and CD8 T cells play a critical role in terminating an acute RSV infection whereas antibodies can provide protection from re-infection. Despite eliciting an immune response that mediates clearance of the virus, immunity to the virus appears to wane over time and individuals remain susceptible to reinfection with RSV throughout their lifetime. The ineffectiveness of the natural infection to induce long-term immunity has hampered vaccine efforts and there is currently no licensed RSV vaccine. In this review, we summarize our current understanding of the adaptive immune response to RSV and its contribution to disease.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24362689     DOI： 10.1007/978-3-642-38919-1_8

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN： 0070-217X            Impact factor:   4.291


  16 in total

Review 1.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 2.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

Review 3.  Determinants of early life immune responses to RSV infection.

Authors:  Tracy J Ruckwardt; Kaitlyn M Morabito; Barney S Graham
Journal:  Curr Opin Virol       Date:  2016-03-15       Impact factor: 7.090

Review 4.  Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.

Authors:  Sara A Taleb; Asmaa A Al Thani; Khalid Al Ansari; Hadi M Yassine
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-06       Impact factor: 3.267

5.  Coptidis Rhizoma extract inhibits replication of respiratory syncytial virus in vitro and in vivo by inducing antiviral state.

Authors:  Byeong-Hoon Lee; Kiramage Chathuranga; Md Bashir Uddin; Prasanna Weeratunga; Myun Soo Kim; Won-Kyung Cho; Hong Ik Kim; Jin Yeul Ma; Jong-Soo Lee
Journal:  J Microbiol       Date:  2017-05-28       Impact factor: 3.422

6.  Respiratory syncytial virus in adults with severe acute respiratory illness in a high HIV prevalence setting.

Authors:  Jocelyn Moyes; Sibongile Walaza; Marthi Pretorius; Michelle Groome; Anne von Gottberg; Nicole Wolter; Sumayya Haffejee; Ebrahim Variava; Adam L Cohen; Stefano Tempia; Kathleen Kahn; Halima Dawood; Marietjie Venter; Cheryl Cohen; Shabir A Madhi
Journal:  J Infect       Date:  2017-07-01       Impact factor: 6.072

Review 7.  Modulation of the host immune response by respiratory syncytial virus proteins.

Authors:  Megan E Schmidt; Steven M Varga
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 2.902

Review 8.  Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus.

Authors:  Silvia Vandini; Paolo Bottau; Giacomo Faldella; Marcello Lanari
Journal:  Biomed Res Int       Date:  2015-05-06       Impact factor: 3.411

Review 9.  Oncolytic virus-mediated reversal of impaired tumor antigen presentation.

Authors:  Shashi A Gujar; Patrick W K Lee
Journal:  Front Oncol       Date:  2014-04-10       Impact factor: 6.244

Review 10.  Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.

Authors:  Clare E French; Bruce C McKenzie; Caroline Coope; Subhadra Rajanaidu; Karthik Paranthaman; Richard Pebody; Jonathan S Nguyen-Van-Tam; Julian P T Higgins; Charles R Beck
Journal:  Influenza Other Respir Viruses       Date:  2016-03-24       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.